PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ <i>neu</i> Oncogene

Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760 · see citing works

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2

Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · see citing works

The phosphoinositide 3-kinase pathway

Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621 · see citing works

<i>PTEN</i> , a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer

Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785 · see citing works

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer

Vogel, C. L., Cobleigh, M., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.3.719 · Cited by 3,240 · see citing works

Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease

Cobleigh, M., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V. E., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,767 · see citing works

New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway

Cantley, L. C., & Neel, B. G. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4240 · Cited by 2,007 · see citing works

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

Cho, H., Mason, K., Ramyar, K. X., Stanley, A. M., Gabelli, S. B., Denney, D. W., & Leahy, D. J. (2003) · Nature · doi:10.1038/nature01392 · Cited by 1,615 · see citing works

The Multiple Roles of PTEN in Tumor Suppression

Di Cristofano, A., & Pandolfi, P. P. (2000) · Cell · doi:10.1016/s0092-8674(00)80674-1 · Cited by 1,182 · see citing works

Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin)

Lu, Y., Zi, X., Zhao, Y., Mascarenhas, D. D., & Pollak, M. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.24.1852 · Cited by 884 · see citing works

Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.

Petit, A. M. V., Rak, J. W., Hung, M., Rockwell, P., Goldstein, N. I., FENDLY, B. M., & Kerbel, R. S. (1997) · Europe PMC (PubMed Central) · Cited by 836 · see citing works

Altered PTEN Expression as a Diagnostic Marker for the Earliest Endometrial Precancers

Mutter, G. L. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.11.924 · Cited by 829 · see citing works

THE IMPACT OF NATIONAL CANCER ACT

Holmes, F. A., Walters, R. S., Theriault, R. L., Buzdar, A. U., Frye, D. K., Hortobágyi, G. N., Forman, A. D., Newton, L. K., & Raber, M. N. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.24.1797 · Cited by 796 · see citing works

Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.

Molina, M. A., Codony‐Servat, J., Albanell, J., Rojo, F., Arribas, J., & Baselga, J. M. (2001) · PubMed · Cited by 766 · see citing works

p185 HER2 Monoclonal Antibody Has Antiproliferative Effects In Vitro and Sensitizes Human Breast Tumor Cells to Tumor Necrosis Factor

Hudziak, R. M., Phillips, G. D. L., Winget, M., FENDLY, B. M., Shepard, H. M., & Ullrich, A. (1989) · Molecular and Cellular Biology · doi:10.1128/mcb.9.3.1165-1172.1989 · Cited by 750 · see citing works

Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast Cancer

Holmes, F. A., Walters, R. S., Theriault, R. L., Buzdar, A. U., Frye, D., Hortobágyi, G. N., Forman, A. D., Newton, L. K., & Raber, M. N. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.24.1797-a · Cited by 744 · see citing works

Src in cancer: deregulation and consequences for cell behaviour

Frame, M. C. (2002) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(02)00040-9 · Cited by 682 · see citing works

Tumor Suppressor PTEN Mediates Sensing of Chemoattractant Gradients

Iijima, M., & Devreotes, P. N. (2002) · Cell · doi:10.1016/s0092-8674(02)00745-6 · Cited by 677 · see citing works

Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).

Sliwkowski, M. X., Ja, L., Gd, L., Te, H., FENDLY, B. M., & Fox, J. A. (1999) · PubMed · Cited by 653 · see citing works

Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression

Whang, Y. E., Wu, X., Suzuki, H., Reiter, R. E., Tran, C., Vessella, R. L., SAID, J. W., Isaacs, W. B., & Sawyers, C. L. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.9.5246 · Cited by 639 · see citing works

Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.

Yakes, F. M., Chinratanalab, W., Ritter, C. A., King, W., SEELIG, S. A., & Arteaga, C. L. (2002) · PubMed · Cited by 611 · see citing works

An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten +/− mice

Podsypanina, K., Lee, R. T., Politis, C., Hennessy, I., Crane, A., Puc, J. A., Neshat, M. S., Wang, H., Yang, L., Gibbons, J., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171060098 · Cited by 570 · see citing works

Phase II Study of Weekly Docetaxel and Trastuzumab for Patients With HER-2–Overexpressing Metastatic Breast Cancer

Esteva, F. J., Valero, V., Booser, D. J., Guerra, L. T., Murray, J. L., Pusztai, L., Cristofanilli, M., Arun, B., Esmaeli, B., Fritsche, H. A., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.07.058 · Cited by 566 · see citing works

Weekly Trastuzumab and Paclitaxel Therapy for Metastatic Breast Cancer With Analysis of Efficacy by HER2 Immunophenotype and Gene Amplification

Seidman, A. D., Fornier, M. N., Esteva, F. J., Tan, L. K., Kaptain, S., Bach, A. M., Panageas, K. S., Arroyo, C. D., Valero, V., Currie, V. E., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.10.2587 · Cited by 546 · see citing works

PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G 1 cell cycle arrest in human glioblastoma cells

Li, D., & Sun, H. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15406 · Cited by 490 · see citing works

MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines.

Teng, D., Hu, R. H., Lin, H., Davis, T., Iliev, D., Frye, C., Swedlund, B., Hansen, K. L., Vinson, V. L., Gumpper, K. L., et al. (1997) · PubMed · Cited by 465 · see citing works

Specificity of HercepTest in Determining HER-2/neu Status of Breast Cancers Using the United States Food and Drug Administration–Approved Scoring System

Jacobs, T. W., Gown, A. M., Yaziji, H., Barnes, M. J., & Schnitt, S. J. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.7.1983 · Cited by 456 · see citing works

Overexpression of ErbB2 in cancer and ErbB2-targeting strategies

Yu, D., & Hung, M. (2000) · Oncogene · doi:10.1038/sj.onc.1203972 · Cited by 431 · see citing works

PTEN: The down side of PI 3-kinase signalling

Leslie, N. R., & Downes, C. P. (2002) · Cellular Signalling · doi:10.1016/s0898-6568(01)00234-0 · Cited by 415 · see citing works

Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies

Drebin, J. A., Link, V. C., Stern, D. F., Weinberg, R. A., & Greene, M. I. (1985) · Cell · doi:10.1016/s0092-8674(85)80050-7 · Cited by 396 · see citing works

Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer.

Valero, V., Holmes, F. A., Walters, R. S., Theriault, R. L., Esparza, L., Fraschini, G., Fonseca, G. A., Bellet, R. E., Buzdar, A. U., & Hortobágyi, G. N. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.12.2886 · Cited by 385 · see citing works

Immunohistochemical Evidence of Loss of PTEN Expression in Primary Ductal Adenocarcinomas of the Breast

Perren, A. A., Weng, L., Boag, A. H., Ziebold, U., Thakore, K. S., Dahia, P. L. M., Komminoth, P., Lees, J. A., Mulligan, L. M., Mutter, G. L., et al. (1999) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65227-3 · Cited by 379 · see citing works

HER-2/neu Blocks Tumor Necrosis Factor-induced Apoptosis via the Akt/NF-κB Pathway

Zhou, B. P., Hu, M. C. ‐., Miller, S. A., Yu, Z., Xia, W., Lin, S., & Hung, M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.11.8027 · Cited by 371 · see citing works

Efp targets 14-3-3σ for proteolysis and promotes breast tumour growth

Urano, T., Saito, T., Tsukui, T., Fujita, M., Hosoi, T., Muramatsu, M., Ouchi, Y., & Inoue, S. (2002) · Nature · doi:10.1038/nature00826 · Cited by 357 · see citing works

Overexpression of ErbB2 Blocks Taxol-Induced Apoptosis by Upregulation of p21Cip1, which Inhibits p34Cdc2 Kinase

Yu, D., Jing, T., Liu, B., Yao, J., Tan, M., McDonnell, T. J., & Hung, M. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80157-4 · Cited by 353 · see citing works

The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells

Lu, Y., Lin, Y.-Z., LaPushin, R., Cuevas, B. D., Fang, X., Yu, S. X., Davies, M. A., Khan, H., Furui, T., Mao, M., et al. (1999) · Oncogene · doi:10.1038/sj.onc.1203183 · Cited by 323 · see citing works

The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region

Georgescu, M.-M., Kirsch, K. H., Akagi, T., Shishido, T., & Hanafusa, H. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.18.10182 · Cited by 318 · see citing works

Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome

Faneyte, I. F., Schrama, J. G., Peterse, J. L., Pl, R., Rodenhuis, S., & van de Vijver, M. J. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600749 · Cited by 307 · see citing works

Loss of Expression of the PTEN Gene Protein Product Is Associated with Poor Outcome in Breast Cancer

Depowski, P. L., Rosenthal, S. I., & Ross, J. S. (2001) · Modern Pathology · doi:10.1038/modpathol.3880371 · Cited by 296 · see citing works

Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic

Shepard, H. M., Phillips, G. D. L., Sarup, J. C., FENDLY, B. M., Maneval, D. C., Mordenti, J. J., Figari, I. S., Kotts, C. E., Palladino, M. A., Ullrich, A., et al. (1991) · Journal of Clinical Immunology · doi:10.1007/bf00918679 · Cited by 295 · see citing works

Molecular targets for breast cancer therapy and prevention

Bange, J., Zwick, E., & Ullrich, A. (2001) · Nature Medicine · doi:10.1038/87872 · Cited by 287 · see citing works

Interaction of the Tumor Suppressor PTEN/MMAC with a PDZ Domain of MAGI3, a Novel Membrane-associated Guanylate Kinase

Wu, Y. L., Dowbenko, D. J., Spencer, S. D., Laura, R. P., Lee, J., Gu, Q., & Lasky, L. A. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m909741199 · Cited by 267 · see citing works

Mechanism of action of anti-HER2 monoclonal antibodies

Baselga, J., & Albanell, J. (2001) · Annals of Oncology · doi:10.1093/annonc/12.suppl_1.s35 · Cited by 266 · see citing works

Src Family Protein-tyrosine Kinases Alter the Function of PTEN to Regulate Phosphatidylinositol 3-Kinase/AKT Cascades

Lu, Y., Yu, Q., Liu, J. H., Zhang, J., Wang, H., Koul, D., McMurray, J. S., Fang, X., Yung, W. K. A., Siminovitch, K. A., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303621200 · Cited by 262 · see citing works

Specific Inhibition of PTEN Expression Reverses Hyperglycemia in Diabetic Mice

Butler, M., McKay, R. A., Popoff, I., Gaarde, W. A., Witchell, D. R., Murray, S. F., Dean, N. M., Bhanot, S., & Monia, B. P. (2002) · Diabetes · doi:10.2337/diabetes.51.4.1028 · Cited by 216 · see citing works

Src family kinases and HER2 interactions in human breast cancer cell growth and survival

Jablonski, A. B., Biscardi, J. S., Peavy, D. R., Tice, D. A., Romney, D. A., & Parsons, S. J. (2001) · Oncogene · doi:10.1038/sj.onc.1204205 · Cited by 185 · see citing works

PI 3-Kinases and PTEN

Comer, F. I., & Parent, C. A. (2002) · Cell · doi:10.1016/s0092-8674(02)00765-1 · Cited by 132 · see citing works

Phosphorylation on Tyrosine-15 of p34Cdc2 by ErbB2 Inhibits p34Cdc2 Activation and Is Involved in Resistance to Taxol-Induced Apoptosis

Tan, M., Jing, T., Lan, K., Neal, C. L., Li, P., Lee, S., Fang, D., Nagata, Y., Liu, J., Arlinghaus, R. B., et al. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00510-5 · Cited by 128 · see citing works

Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol

Yu, D., Liu, B., Jing, T., Sun, D., Price, J. E., Singletary, S. E., Ibrahim, N., Hortobágyi, G. N., & Hung, M. (1998) · Oncogene · doi:10.1038/sj.onc.1201729 · Cited by 127 · see citing works

Immunohistochemical expression of the c-kit proto-oncogene product in human malignant and non-malignant breast tissues

Chui, X., Egami, H., Yamashita, J., Kurizaki, T., Ohmachi, H., Yamamoto, S., & Ogawa, M. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.236 · Cited by 117 · see citing works

Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells.

Lee, S., Yang, W., Lan, K., Sellappan, S., Klos, K. S., Hortobágyi, G. N., Hung, M., & Yu, D. (2002) · PubMed · Cited by 109 · see citing works

Roles of plakoglobin end domains in desmosome assembly

Palka, H. L., & Green, K. J. (1997) · Journal of Cell Science · doi:10.1242/jcs.110.19.2359 · Cited by 109 · see citing works

Peripheral nerve sheath tumors histogenesis, classification, and prognosis

Hajdu, S. I. (1993) · Cancer · doi:10.1002/1097-0142(19931215)72:12 · Cited by 102 · see citing works

ERBB-2 overexpression confers PI 3′ kinase-dependent invasion capacity on human mammary epithelial cells

Ignatoski, K. M. W., Maehama, T., Markwart, S. M., Dixon, J. E., Livant, D. L., & Ethier, S. P. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.0979 · Cited by 95 · see citing works

Up-regulation of vascular endothelial growth factor in breast cancer cells by the heregulin-beta1-activated p38 signaling pathway enhances endothelial cell migration.

Xiong, S., Grijalva, R., Zhang, L., Nguyen, N. T., Pisters, P. W. T., Pollock, R. E., & Yu, D. (2001) · PubMed · Cited by 92 · see citing works

PTEN and cancer.

Parsons, R., & Simpson, L. (2003) · Methods in molecular biology · doi:10.1385/1-59259-328-3:147 · Cited by 89 · see citing works

Unraveling Resistance to Trastuzumab (Herceptin): Insulin-Like Growth Factor-I Receptor, a New Suspect

Albanell, J., & Baselga, J. M. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.24.1830 · Cited by 88 · see citing works

Activation of Src family kinases in Neu-induced mammary tumors correlates with their association with distinct sets of tyrosine phosphorylated proteins in vivo.

Muthuswamy, S. K., & Wj, M. (1995) · PubMed · Cited by 78 · see citing works

Heregulin beta1-activated phosphatidylinositol 3-kinase enhances aggregation of MCF-7 breast cancer cells independent of extracellular signal-regulated kinase.

Tan, M., Grijalva, R., & Yu, D. (1999) · PubMed · Cited by 61 · see citing works

Motif analysis of the tumor suppressor gene MMAC/PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activity

Koul, D., Jasser, S. A., Lu, Y., Davies, M. A., Shen, R., Shi, Y., Mills, G. B., & Yung, W. A. (2002) · Oncogene · doi:10.1038/sj.onc.1205296 · Cited by 55 · see citing works

Motif analysis of the tumor suppressor gene MMAC/PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activity

Koul, D., Jasser, S. A., Lu, Y., et al. (2002) · Oncogene · doi:10.1038/sj/onc/1205296 · Cited by 51 · see citing works

Antibodies Stage a Comeback in Cancer Treatment

Dickman, S. (1998) · Science · doi:10.1126/science.280.5367.1196 · Cited by 46 · see citing works

Src Phosphorylates Grb2-associated Binder 1 upon Hepatocyte Growth Factor Stimulation

Chan, P.-C., Chen, Y., Cheng, C.-H., Yu, K.-C., Cary, L. A., Shu, K., Ho, W. L., & Chen, H. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305745200 · Cited by 44 · see citing works

Monoclonal Antibody Therapy of Human Cancer

Foon, K. A., & Morgan, A. C. (2012) · Medical Entomology and Zoology · Cited by 12 · see citing works

Src in cancer

Frame, M. C. (2002) · Biochimica et Biophysica Acta · Cited by 3 · see citing works

Cancer drug resistance: an evolving paradigm

Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681 · see citing works

ERBB receptors and cancer: the complexity of targeted inhibitors

Hynes, N. E., & Lane, H. A. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1609 · Cited by 3,313 · see citing works

EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer

Singh, A., & Settleman, J. (2010) · Oncogene · doi:10.1038/onc.2010.215 · Cited by 2,545 · see citing works

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

Engelman, J. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2664 · Cited by 2,445 · see citing works

Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery

Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y., & Mills, G. B. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1902 · Cited by 2,183 · see citing works

EGF–ERBB signalling: towards the systems level

Citri, A., & Yarden, Y. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1962 · Cited by 2,004 · see citing works

Comprehensive review of targeted therapy for colorectal cancer

Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0116-z · Cited by 1,687 · see citing works

Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate

Phillips, G. D. L., Li, G., Dugger, D. L., Crocker, L., Parsons, K. L., Mai, E., Blättler, W. A., Lambert, J. M., Chari, R. V. J., Lutz, R. J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1776 · Cited by 1,679 · see citing works

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

Berns, K., Horlings, H. M., Hennessy, B. T., Madiredjo, M., Hijmans, E. M., Beelen, K., Linn, S. C., Gonzalez-Angulo, A. M., Stemke-Hale, K., Hauptmann, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.030 · Cited by 1,627 · see citing works

PI3K pathway alterations in cancer: variations on a theme

Yuan, T. L., & Cantley, L. C. (2008) · Oncogene · doi:10.1038/onc.2008.245 · Cited by 1,845 · see citing works

Tyrosine Kinases as Targets for Cancer Therapy

Krause, D. S., & Etten, R. A. V. (2005) · New England Journal of Medicine · doi:10.1056/nejmra044389 · Cited by 1,376 · see citing works

Lipid signalling in disease

Wymann, M. P., & Schneiter, R. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2335 · Cited by 1,285 · see citing works

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial

Loi, S., Michiels, S., Salgado, R., Sirtaine, N., José, V., Fumagalli, D., Kellokumpu‐Lehtinen, P., Bono, P., Kataja, V. V., Desmedt, C., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu112 · Cited by 1,257 · see citing works

Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth

Zhang, L., Zhang, S., Yao, J., Lowery, F. J., Zhang, Q., Huang, W.-C., Li, P., Li, M., Wang, X., Zhang, C., et al. (2015) · Nature · doi:10.1038/nature15376 · Cited by 1,080 · see citing works

The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine

Ross, J. S., Slodkowska, E. A., Symmans, W. F., Pusztai, L., Ravdin, P. M., & Hortobágyi, G. N. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0230 · Cited by 1,144 · see citing works

Novel anticancer targets: revisiting ERBB2 and discovering ERBB3

Baselga, J. M., & Swain, S. M. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2656 · Cited by 1,144 · see citing works

Combinatorial drug therapy for cancer in the post-genomic era

Al-Lazikani, B., Banerji, U., & Workman, P. (2012) · Nature Biotechnology · doi:10.1038/nbt.2284 · Cited by 1,070 · see citing works

An integrative genomic and proteomic analysis of pik3ca, pten, and akt mutations in breast cancer.

Stemke-Hale, K., Gonzalez-Angulo, A. M., Lluch, A., Neve, R. M., Kuo, W.-L., Davies, M., Carey, M., Hu, Z., Guan, Y., Sahin, A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6854 · Cited by 1,054 · see citing works

ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics

Arteaga, C. L., & Engelman, J. A. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.025 · Cited by 1,048 · see citing works

Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling

Wagle, N., Emery, C., Berger, M. F., Davis, M. J., Sawyer, A. M., Pochanard, P., Kehoe, S. M., Johannessen, C. M., MacConaill, L. E., Hahn, W. C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.2312 · Cited by 996 · see citing works

Current development of mTOR inhibitors as anticancer agents

Faivre, S. J., Kroemer, G., & Raymond, É. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2062 · Cited by 998 · see citing works

The ERBB network: at last, cancer therapy meets systems biology

Yarden, Y., & Pines, G. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3309 · Cited by 998 · see citing works

Targeting cellular metabolism to improve cancer therapeutics

Zhao, Y., Butler, E. B., & Tan, M. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.60 · Cited by 994 · see citing works

ErbB receptors and signaling pathways in cancer

Hynes, N. E., & MacDonald, G. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2008.12.010 · Cited by 956 · see citing works

Molecular Classification and Molecular Forecasting of Breast Cancer: Ready for Clinical Application?

Brenton, J. D., Carey, L., Ahmed, A. A., & Caldas, C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.3845 · Cited by 953 · see citing works

Overview of resistance to systemic therapy in patients with breast cancer

Gonzalez-Angulo, A. M., Morales-Vasquez, F., & Hortobagyi, G. N. (2007) · Advances in Experimental Medicine and Biology · doi:10.1007/978-0-387-74039-3_1 · Cited by 904 · see citing works

Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer

Nahta, R., Yu, D., Hung, M., Hortobágyi, G. N., & Esteva, F. J. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0509 · Cited by 916 · see citing works

Activity of the Dual Kinase Inhibitor Lapatinib (GW572016) against HER-2-Overexpressing and Trastuzumab-Treated Breast Cancer Cells

Konecny, G. E., Pegram, M. D., Venkatesan, N., Finn, R. S., Yang, G., Rahmeh, M., Untch, M., Rusnak, D. W., Spehar, G. M., Mullin, R. J., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1182 · Cited by 916 · see citing works

Breast cancer intrinsic subtype classification, clinical use and future trends.

Dai, X., Li, T., Bai, Z., Yang, Y., Liu, X., Zhan, J., & Shi, B. (2015) · Europe PMC (PubMed Central) · Cited by 886 · see citing works

Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer

Scaltriti, M., Rojo, F., Ocana, A., Anido, J., Guzman, M., Cortes, J., Di Cosimo, S., Matias-Guiu, X., Ramon y Cajal, S., Arribas, J., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk134 · Cited by 895 · see citing works

PIK3CA Mutations Correlate with Hormone Receptors, Node Metastasis, and ERBB2, and Are Mutually Exclusive with PTEN Loss in Human Breast Carcinoma

Saal, L. H., Holm, K., Maurer, M. S., Memeo, L., Su, T., Wang, X., Yu, J. S., Malmström, P.-O., MANSUKHANI, M. M., Enoksson, J., et al. (2005) · Cancer Research · doi:10.1158/0008-5472-can-04-3913 · Cited by 877 · see citing works

Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941

Junttila, T. T., Akita, R. W., Parsons, K. L., Fields, C. T., Phillips, G. D. L., Friedman, L. S., Sampath, D., & Sliwkowski, M. X. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.020 · Cited by 829 · see citing works

NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations

Serra, V., Markman, B., Scaltriti, M., Eichhorn, P. J. A., Valero, V., Guzman, M., Botero, M. L., Llonch, E., Atzori, F., Di Cosimo, S., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1385 · Cited by 787 · see citing works

Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations

LoPiccolo, J., Blumenthal, G. M., Bernstein, W. B., & Dennis, P. A. (2008) · Drug Resistance Updates · doi:10.1016/j.drup.2007.11.003 · Cited by 804 · see citing works

PTEN loss in the continuum of common cancers, rare syndromes and mouse models

Hollander, M. C., Blumenthal, G. M., & Dennis, P. A. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3037 · Cited by 793 · see citing works

Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells

Nahta, R., Yuan, L. X. H., Zhang, B., Kobayashi, R., & Esteva, F. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3841 · Cited by 793 · see citing works

Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer

Yu, L., Wei, J., & Liu, P. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.06.019 · Cited by 785 · see citing works

The Identification of 2-(1 H -Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2- d ]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer

Folkes, A. J., Ahmadi, K., ALDERTON, W. K., Alix, S., Baker, S. J., Box, G., Chuckowree, I., Clarke, P. A., Depledge, P., Eccles, S. A., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800295d · Cited by 756 · see citing works

<i>PIK3CA</i> Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies

Sartore-Bianchi, A., Martini, M., Molinari, F., Veronese, S., Nichelatti, M., Artale, S., Di Nicolantonio, F., Saletti, P., De Dosso, S., Mazzucchelli, L., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2466 · Cited by 739 · see citing works

Analysis of <i>PTEN</i> , <i>BRAF</i> , and <i>EGFR</i> Status in Determining Benefit From Cetuximab Therapy in Wild-Type <i>KRAS</i> Metastatic Colon Cancer

Laurent-Puig, P., Cayre, A., Manceau, G., Buc, E., Bachet, J.-B., Lecomte, T., Rougier, P., Lievre, A., Landi, B., Boige, V., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6796 · Cited by 673 · see citing works

The relation between PI3K/AKT signalling pathway and cancer

Noorolyai, S., Shajari, N., Baghbani, E., Sadreddini, S., & Baradaran, B. (2019) · Gene · doi:10.1016/j.gene.2019.02.076 · Cited by 661 · see citing works

Targeting the mTOR Signaling Network for Cancer Therapy

Meric‐Bernstam, F., & Gonzalez-Angulo, A. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.0766 · Cited by 639 · see citing works

Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer

Valabrega, G., Montemurro, F., & Aglietta, M. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl475 · Cited by 627 · see citing works

Trastuzumab: Updated Mechanisms of Action and Resistance in Breast Cancer

Vu, T. T., & Claret, F. X. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00062 · Cited by 607 · see citing works

KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer

Roock, W. D., de Vriendt, V., Normanno, N., Ciardiello, F., & Tejpar, S. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70209-6 · Cited by 605 · see citing works

Trastuzumab emtansine: mechanisms of action and drug resistance

Barok, M., Joensuu, H., & Isola, J. J. (2014) · Breast Cancer Research · doi:10.1186/bcr3621 · Cited by 601 · see citing works

EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance

Uribe, M. L., Marrocco, I., & Yarden, Y. (2021) · Cancers · doi:10.3390/cancers13112748 · Cited by 604 · see citing works

Integrin-linked kinase: a cancer therapeutic target unique among its ILK

Hannigan, G. E., Troussard, A. A., & Dedhar, S. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1524 · Cited by 589 · see citing works

ErbB receptors: from oncogenes to targeted cancer therapies

Zhang, H., Berezov, A., Wang, Q., Zhang, G., Drebin, J. A., Murali, R., & Greene, M. I. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32278 · Cited by 573 · see citing works

HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion

Körkaya, H., Paulson, A. K., Iovino, F., & Wicha, M. S. (2008) · Oncogene · doi:10.1038/onc.2008.207 · Cited by 557 · see citing works

Enabling personalized cancer medicine through analysis of gene-expression patterns

Veer, L. V. ‘., & Bernards, R. (2008) · Nature · doi:10.1038/nature06915 · Cited by 556 · see citing works

Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer

Junttila, T. T., Li, G., Parsons, K. L., Phillips, G. D. L., & Sliwkowski, M. X. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1090-x · Cited by 542 · see citing works

Activation of an IL-6 Inflammatory Loop Mediates Trastuzumab Resistance in HER2 Overexpressing Breast Cancers by Expanding the Cancer Stem Cell Population

Korkaya, H., Kim, G., Davis, A., Malik, F., Henry, N., Ithimakin, S., Quraishi, A. A., Tawakkol, N., D'Angelo, R., Paulson, A. K., et al. (2012) · Molecules and Cells · doi:10.1016/j.molcel.2012.06.014 · Cited by 518 · see citing works

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

Serra, V., Scaltriti, M., Prudkin, L., Eichhorn, P. J. A., Ibrahim, Y. H., Chandarlapaty, S., Markman, B., Rodríguez, O., Guzmán, M., Rodriguez, S., et al. (2011) · Oncogene · doi:10.1038/onc.2010.626 · Cited by 533 · see citing works

Regulation of mammary stem/progenitor cells by PTEN/Akt/β-catenin signaling

Korkaya, H., Paulson, A., Charafe-Jauffret, E., Ginestier, C., Brown, M., Dutcher, J., Clouthier, S. G., & Wicha, M. S. (2009) · PLoS Biology · doi:10.1371/journal.pbio.1000121 · Cited by 523 · see citing works

Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal Cancer

Siena, S., Bianchi, A. S., Nicolantonio, F. D., Balfour, J., & Bardelli, A. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp280 · Cited by 526 · see citing works

Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways

Zhang, S., Huang, W.-C., Li, P., Guo, H., Poh, S.-B., Brady, S. W., Xiong, Y., Tseng, L.-M., Li, S.-H., Ding, Z., et al. (2011) · Nature Medicine · doi:10.1038/nm.2309 · Cited by 515 · see citing works

Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity

Saal, L. H., Johansson, P. A., Holm, K., Gruvberger-Saal, S. K., She, Q., Maurer, M. S., Koujak, S., Ferrando, A. A., Malmström, P., Memeo, L., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702507104 · Cited by 514 · see citing works

Breast Cancer–Associated PIK3CA Mutations Are Oncogenic in Mammary Epithelial Cells

Isakoff, S. J., Engelman, J. A., Irie, H. Y., Luo, J., Brachmann, S. M., Pearline, R. V., Cantley, L. C., & Brugge, J. S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2612 · Cited by 505 · see citing works

Resistance to Trastuzumab in Breast Cancer

Pohlmann, P. R., Mayer, I. A., & Mernaugh, R. L. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0636 · Cited by 506 · see citing works

Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors

Goel, S., Wang, Q., Watt, A. C., Tolaney, S. M., Dillon, D. A., Li, W., Ramm, S., Palmer, A. C., Yuzugullu, H., Varadan, V., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.006 · Cited by 470 · see citing works

Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235

Eichhorn, P. J. A., Gili, M., Scaltriti, M., Serra, V., Guzman, M., Nijkamp, W., Beijersbergen, R. L., Valero, V., Seoane, J., Bernards, R., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1740 · Cited by 499 · see citing works

The Akt/PKB pathway: molecular target for cancer drug discovery

Cheng, J. Q., Lindsley, C. W., Cheng, G. Z., Yang, H., & Nicosia, S. V. (2005) · Oncogene · doi:10.1038/sj.onc.1209088 · Cited by 496 · see citing works

Human Breast Cancer Cells Selected for Resistance to Trastuzumab <i>In vivo</i> Overexpress Epidermal Growth Factor Receptor and ErbB Ligands and Remain Dependent on the ErbB Receptor Network

Ritter, C. A., Perez-Torres, M., Rinehart, C., Guix, M., Dugger, T., Engelman, J. A., & Arteaga, C. L. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0701 · Cited by 497 · see citing works

Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

Spector, N. L., & Blackwell, K. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.1507 · Cited by 497 · see citing works

Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL

Liu, L., Greger, J., Shi, H., Liu, Y., Greshock, J., Annan, R., Halsey, W., Sathe, G. M., Martin, A.-M., & Gilmer, T. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4490 · Cited by 495 · see citing works

HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies

Gajria, D., & Chandarlapaty, S. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.226 · Cited by 494 · see citing works

Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial

André, F., O'Regan, R. M., Özgüroğlu, M., Toi, M., Xu, B., Jérusalem, G., Masuda, N., Wilks, S. T., Arena, F. P., Isaacs, C. J., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70138-x · Cited by 493 · see citing works

PTEN Tumor Suppressor Network in PI3K-Akt Pathway Control

Georgescu, M. (2010) · Genes & Cancer · doi:10.1177/1947601911407325 · Cited by 490 · see citing works

Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background

Davies, B. R., Greenwood, H., Dudley, P., Crafter, C., Yu, D.-H., Zhang, J., Li, J., Gao, B., Ji, Q., Maynard, J., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0824-t · Cited by 480 · see citing works

A robustness-based approach to systems-oriented drug design

Kitano, H. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2195 · Cited by 488 · see citing works

Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells

Shattuck, D. L., Miller, J. K., Carraway, K. L., & Sweeney, C. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5962 · Cited by 473 · see citing works

PI3K/Akt/mTOR pathway as a target for cancer therapy

Morgensztern, D., & McLeod, H. L. (2005) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000173476.67239.3b · Cited by 467 · see citing works

PTEN: Multiple Functions in Human Malignant Tumors

Milella, M., Falcone, I., Conciatori, F., Incani, U. C., Curatolo, A. D., Inzerilli, N., Nuzzo, C., Vaccaro, V., Vari, S., Cognetti, F., et al. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00024 · Cited by 429 · see citing works

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer

Engelman, J. A., Mukohara, T., Zejnullahu, K., Lifshits, E., Borras, A. M., Gale, C.-M., Naumov, G. N., Yeap, B. Y., Jarrell, E., Sun, J., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28656 · Cited by 457 · see citing works

Herceptin: mechanisms of action and resistance

Nahta, R., & Esteva, F. J. (2005) · Cancer Letters · doi:10.1016/j.canlet.2005.01.041 · Cited by 446 · see citing works

The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer

Hsu, J. L., & Hung, M. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9649-6 · Cited by 451 · see citing works

A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response

Chen, Z., Cheng, K., Walton, Z., Wang, Y., Ebi, H., Shimamura, T., Liu, Y., Tupper, T., Ouyang, J., Li, J., et al. (2012) · Nature · doi:10.1038/nature10937 · Cited by 446 · see citing works

Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway

Burris, H. A. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-2043-3 · Cited by 446 · see citing works

HER2 therapy: Molecular mechanisms of trastuzumab resistance

Nahta, R., & Esteva, F. J. (2006) · Breast Cancer Research · doi:10.1186/bcr1612 · Cited by 433 · see citing works

Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib

Carey, L., Berry, D. A., Cirrincione, C., Barry, W. T., Pitcher, B. N., Harris, L. N., Ollila, D. W., Krop, I. E., Henry, N. L., Weckstein, D. J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.1268 · Cited by 421 · see citing works

mTOR signaling and drug development in cancer

Dancey, J. E. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.21 · Cited by 418 · see citing works

PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment

Zotano, Á. G., Mayer, I. A., & Arteaga, C. L. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9637-x · Cited by 419 · see citing works

Molecular aspects of cancer cell resistance to chemotherapy

Rebucci, M., & Michiels, C. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.02.017 · Cited by 409 · see citing works

PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.

Loupakis, F., Pollina, L., Stasi, I., Ruzzo, A., Scartozzi, M., Santini, D., Masi, G., Graziano, F., Cremolini, C., Rulli, E., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.2796 · Cited by 403 · see citing works

Targeting the androgen receptor pathway in prostate cancer

Chen, Y., Sawyers, C. L., & Scher, H. I. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.07.005 · Cited by 393 · see citing works

A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer

Xia, W., Bacus, S., Hegde, P., Husain, I., Strum, J., Liu, L., Paulazzo, G., Lyass, L., Trusk, P., Hill, J., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602468103 · Cited by 374 · see citing works

Intrinsic and Acquired Resistance to HER2-Targeted Therapies in HER2 Gene-Amplified Breast Cancer: Mechanisms and Clinical Implications

Rexer, B. N., & Arteaga, C. L. (2012) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.v17.i1.20 · Cited by 372 · see citing works

Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review)

Nițulescu, G. M., Margina, D. M., Juzenas, P., Peng, Q., Olaru, O. T., Saloustros, E. S., Fenga, C., Spandidos, D. A., Libra, M., & Tsatsakis, A. M. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3306 · Cited by 370 · see citing works

A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine

Krop, I. E., LoRusso, P. M., Miller, K. D., Modi, S., Yardley, D. A., Rodriguez, G., Guardino, E., Lu, M. W., Zheng, M., Girish, S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.5902 · Cited by 366 · see citing works

Targeting breast cancer stem cells.

Liu, S.-L., & Wicha, M. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.5388 · Cited by 131 · see citing works

The role of PTEN signaling perturbations in cancer and in targeted therapy

Keniry, M. E., & Parsons, R. E. (2008) · Oncogene · doi:10.1038/onc.2008.248 · Cited by 358 · see citing works

Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer

Coley, H. M. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.01.007 · Cited by 352 · see citing works

HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance

Pernas, S., & Tolaney, S. M. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919833519 · Cited by 353 · see citing works

Physiological regulation of Akt activity and stability.

Liao, Y., & Hung, M. (2010) · PubMed Central · Cited by 343 · see citing works

The Role of Src in Solid Tumors

Wheeler, D. L., Iida, M., & Dunn, E. F. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0009 · Cited by 346 · see citing works

Identification of the <i>miR-106b</i> ~ <i>25</i> MicroRNA Cluster as a Proto-Oncogenic <i>PTEN</i> -Targeting Intron That Cooperates with Its Host Gene <i>MCM7</i> in Transformation

Poliseno, L., Salmena, L., Riccardi, L., Fornari, A., Song, M. S., Hobbs, R. M., Sportoletti, P., Varmeh, S., Egia, A., Fedele, G., et al. (2010) · Science Signaling · doi:10.1126/scisignal.2000594 · Cited by 410 · see citing works

Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial

Sweeney, C. J., Sergio Bracarda, A., Sternberg, C. N., Chi, K. N., Olmos, D., Sandhu, S. K., Massard, C., Matsubara, N., Alekseev, B. Y., Parnis, F., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00580-8 · Cited by 340 · see citing works

Mechanisms of resistance to anti-EGFR therapy in colorectal cancer

Zhao, B., Wang, L., Qiu, H., Zhang, M., Sun, L., Peng, P., Yu, Q., & Yuan, X. (2017) · Oncotarget · doi:10.18632/oncotarget.14012 · Cited by 319 · see citing works

Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2 ⁺ breast cancer patients

Scaltriti, M., Eichhorn, P. J., Cortés, J., Prudkin, L., Aura, C., Jiménez, J., Chandarlapaty, S., Serra, V., Prat, A., Ibrahim, Y. H., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014835108 · Cited by 337 · see citing works

Successful targeting of ErbB2 receptors—is PTEN the key?

Crowder, R. J., Lombardi, D. P., & Ellis, M. J. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.08.001 · Cited by 24 · see citing works

PI3 Kinase Activation and Response to Trastuzumab Therapy: What's neu with Herceptin Resistance?

Park, B. H., & Davidson, N. E. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.10.004 · Cited by 47 · see citing works

PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer

Fujita, T., Kawasaki, K., Takabatake, D., Takahashi, H., Ogasawara, Y., & Doihara, H. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.10026 · Cited by 3 · see citing works

PTEN loss is not associated with trastuzumab resistance in metastatic breast cancer.

Kocar, M., Bozkurtlar, E. B., Telli, F., Turhal, N. S., Kaya, H., Kocar, H., & Yumuk, F. (2014) · PubMed · Cited by 6 · see citing works

PTEN, PIK3CA, p-AKT, and p-p70S6K Status

Esteva, F. J., Guo, H., Zhang, S., Santa-Maria, C., Stone, S., Lanchbury, J. S., Sahin, A. A., Hortobagyi, G. N., & Yu, D. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.090885 · Cited by 285 · see citing works